PharmaShots | Incisive News in 3 Shots

Subscribe Now

All Posts by Date

PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Metastatic Melanoma Trial Presented at AACR 2022

PharmaShots Interview: In Conversation with IO Biotech’s CEO, Mai-Britt Zocca, Where she Shares Insights on the New Data from Met...

June 28, 2022

$Kite’s Yescarta (axicabtagene ciloleucel) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma$

Kite’s Yescarta (axicabtagene ciloleucel) Receives EC’s Approval for the Treatment of Relapsed or Refractory Follicular Lymphoma

June 28, 2022

AstraZeneca and Merck Receive CHMP Positive Opinion of Lynparza (olaparib) as Adjuvant Treatment for HER2-Negative High-Risk Early Breast Cancer

AstraZeneca and Merck Receive CHMP Positive Opinion of Lynparza (olaparib) as Adjuvant Treatment for HER2-Negative High-Risk Early...

June 28, 2022

Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at EAN 2022

Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at...

June 28, 2022

Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia

Basilea Reports Results of Ceftobiprole in the P-III (ERADICATE) Study for the Treatment of Staphylococcus Aureus Bacteremia

June 28, 2022

Astellas Reports the US FDA’s Clinical Hold on the P-I/II (FORTIS) Trial of AT845 for the Treatment of Adults with Late-Onset Pompe Disease

Astellas Reports the US FDA’s Clinical Hold on the P-I/II (FORTIS) Trial of AT845 for the Treatment of Adults with Late-Onset Pomp...

June 28, 2022

Contact Us

First Floor, B 150, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
[email protected]
Newsletter

Our Information

Follow Us